Navigation Links
Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
Date:9/6/2007

- Sabila Industrial Originally Certified ISO in January 2003

- No Incidences of Nonconformance Found for Last Two Years - Auditors Stated, "First Time Any Company They Audited Performed at Such a

High Quality Level"

- Company Dedicated to Quality

IRVING, Texas, Sept. 6 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Pink Sheets: CARN) today announced that its bulk pharmaceutical manufacturing subsidiary, Sabila Industrial, S.A., located in Liberia, Guanacaste, Costa Rica, has completed an annual ISO 9001:2000 re-certification inspection by the European Union's notified body, AENOR Internacional, S.A.U. of Madrid, Spain.

Mr. Jose Zuniga, Carrington's vice president of operations and manager of South American business, stated, "The Chief Inspector representing AENOR Internacional stated that this is the first time any company audited by his team has performed at such a high quality level that no nonconformances with ISO quality systems have been found over a two-year period. We at Carrington, and in particular Sabila Industrial, are delighted that our quality systems are recognized by an EU's notified body. We credit our frequent quality audits in Costa Rica and at our manufacturing facilities in Texas as key to our success."

Mr. Zuniga added, "Using organic certified plant materials, our Costa Rica plant manufactures the GelSite(R) polymer, the raw material key to the drug and vaccine delivery technology being developed by Carrington's biotech subsidiary DelSite Biotechnologies, Inc. GelSite(R) is used to make the influenza nasal powder vaccine for bird flu (H5N1). Additionally, our corporate site in Texas uses organic methods on its grounds, our Costa Rica farming operation is certified organic, and our raw material Manapol(R) is kosher certified. These certifications and quality systems are not inexpensive, but they show our dedication to quality. These inspection results let our customers and potential customers know that, as a corporation, we are dedicated to developing, implementing, and maintaining the highest quality standards for the protection of those who use our raw materials and finished products."

About Sabila Industrial

Sabila Industrial, S.A. is a wholly owned subsidiary of Carrington Laboratories, Inc. dedicated to producing raw materials for oral care, wound care, and consumer products manufactured by Carrington and GelSite(R) for DelSite Biotechnologies, Inc. All naturally derived polymeric raw materials are produced under the FDA's cGMP standards for use in human drugs. An injectable biologic raw material to treat fibrosarcoma in companion animals is produced by Sabila under USDA biologic regulations. Sabila Industrial, S.A. operates in a duty-free zone with an adjacent farm, Finca Sabila, which is certified organic by an agency of the Costa Rican government and recognized by the USDA and the European Union.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , February 12, 2016 ... Efforts by Enabling Scientific Understanding of Complex Diseases ... Rare Diseases --> ... diagnostics in South Asia and a leading provider of ... contribute $10 million to the GenomeAsia 100K consortium ...
(Date:2/11/2016)... Germany and GERMANTOWN, ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... RNA Panels for gene expression profiling, expanding QIAGEN,s portfolio ... The panels enable researchers to select from over 20,000 ... and discover interactions between genes, cellular phenotypes and disease ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, ... sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in the ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... than 150 years, continues today to pursue the highest level of accuracy and ... instruments: the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and tough ...
Breaking Biology Technology:
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/27/2016)... 2016  Rite Track, Inc. a leading semiconductor equipment ... Chester, Ohio announced today the acquisition of PLUS ... in Austin, Texas , will significantly ... modifications, installations and technical support offerings for TEL Track ... commented, "PLUS has provided world class service including refurbishment, ...
Breaking Biology News(10 mins):